Liver Transplantation最新文献

筛选
英文 中文
Prospective evaluation of cystatin C in the assessment of kidney dysfunction and survival in liver transplant candidates. 前瞻性评估胱抑素 C 在肝移植候选者肾功能障碍和存活率评估中的应用。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-24 DOI: 10.1097/LVT.0000000000000492
Stevan A Gonzalez, Nagasri Shankar, Ashwini Mehta, Mauricio Garcia-Saenz-de-Sicilia, Goran B Klintmalm, James F Trotter, Sumeet K Asrani, Bernard V Fischbach, Andres Duarte-Rojo
{"title":"Prospective evaluation of cystatin C in the assessment of kidney dysfunction and survival in liver transplant candidates.","authors":"Stevan A Gonzalez, Nagasri Shankar, Ashwini Mehta, Mauricio Garcia-Saenz-de-Sicilia, Goran B Klintmalm, James F Trotter, Sumeet K Asrani, Bernard V Fischbach, Andres Duarte-Rojo","doi":"10.1097/LVT.0000000000000492","DOIUrl":"10.1097/LVT.0000000000000492","url":null,"abstract":"<p><p>Kidney dysfunction is associated with decreased survival in liver transplant (LT) candidates, yet serum creatinine (sCr) is a poor surrogate for glomerular filtration rate (GFR) in this population. Serum cystatin C (CysC) may provide a more accurate assessment of kidney function and predict outcomes. We performed a multicenter prospective cohort study of consecutive candidates for LT. CysC was obtained at LT evaluation (n = 244), and a subset underwent simultaneous I 125 -iothalamate clearance for measured GFR (mGFR) assessment (n = 137). Patients were followed to assess the need for pre-LT renal replacement therapy, simultaneous liver and kidney transplant, and survival. Estimated GFR (eGFR) based on MDRD-4, GRAIL, Royal Free Hospital Cirrhosis GFR, and the CKD-EPI equations was assessed for bias, precision, and accuracy in reference to mGFR. Receiver operator characteristic (AUROC) and competing risk survival analyses were performed. CysC more accurately discriminated mGFR than sCr at thresholds of ≤60 and ≤30 mL/min/1.73 m 2 with AUROC 0.92 ( p = 0.005) and 0.96 ( p =0.01), respectively. All eGFR equations overestimated GFR, especially among females ( p < 0.05). The GRAIL equation demonstrated the least bias, while CKD-EPI-cystatin C was associated with the greatest precision and lowest frequency of GFR overestimation. Among 165 recipients of LT, CysC discriminated pre-LT renal replacement therapy and the need for simultaneous liver and kidney transplant with AUROC of 0.70 and 0.85, respectively. Cumulative incidence of death, accounting for LT as a competing event, increased with CysC ( p = 0.002) but was not observed with sCr overall or among subgroups ( p = NS). CysC more accurately predicts thresholds of mGFR than sCr in candidates for LT. Elevated CysC discriminates pre-LT renal replacement therapy and simultaneous liver and kidney transplant and is strongly associated with survival in contrast with sCr. CysC is a promising tool to improve prognostication among candidates for LT.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and risk factors for chronic rejection in pediatric liver transplantation. 小儿肝移植中慢性排斥反应的发生率和风险因素。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-24 DOI: 10.1097/LVT.0000000000000488
Peace N Dike, Deborah Schady, Ryan Himes, John A Goss, Danielle Guffey, Dana Cerminara, Krupa R Mysore
{"title":"Incidence and risk factors for chronic rejection in pediatric liver transplantation.","authors":"Peace N Dike, Deborah Schady, Ryan Himes, John A Goss, Danielle Guffey, Dana Cerminara, Krupa R Mysore","doi":"10.1097/LVT.0000000000000488","DOIUrl":"10.1097/LVT.0000000000000488","url":null,"abstract":"<p><p>Chronic rejection (CR) is a progressive immunological injury that frequently leads to long-term liver allograft dysfunction and loss. Although CR remains an important indication for retransplantation, as transplant immunosuppression has evolved, its prevalence in adults undergoing liver transplantation (LT) has declined. However, the incidence and factors that lead to CR in pediatric LT are poorly defined. Therefore, we sought to systematically measure CR's incidence and assess both the risk factors for developing CR and outcomes in a large cohort of pediatric recipients of LT. In this single-center study, we retrospectively analyzed and compared relevant recipient characteristics, surgical details, immunosuppression, graft, and patient survival in the CR and control groups over a 17-year period. After a median time of 1.9 years after LT, 19/356 recipients of LT (5.3%) developed CR in our cohort. Posttransplant lymphoproliferative disorder ( p = 0.01), infections ( p = 0.02), autoimmune liver diseases (HR = 7.3, p = <0.01), Black race (HR = 11.5, p = 0.01), and 2 or more episodes of T cell mediated rejection (HR = 5.1, p = <0.01) were associated with CR development. The retransplantation rate among CR cases was 15.8% at a median follow-up time of 4.1 years. Overall, patient survival was lower in the CR group (78.9%) versus controls (91.1%). While CR incidence in our pediatric cohort was lower than previously reported rates of >12%, the CR group had a higher graft failure rate that required retransplantation and lower overall patient survival. Thus, identifying risk factors may warrant specialized immunosuppression protocols and closer posttransplantation monitoring to reduce the risk of morbidity and mortality from CR.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PRO: Is Management of ACLF better in a liver-dedicated ICU? 专业:肝脏专用重症监护病房对 ACLF 的管理是否更好?
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-20 DOI: 10.1097/LVT.0000000000000490
Hima Veeramachaneni, Nader Dbouk, Ram Subramanian
{"title":"PRO: Is Management of ACLF better in a liver-dedicated ICU?","authors":"Hima Veeramachaneni, Nader Dbouk, Ram Subramanian","doi":"10.1097/LVT.0000000000000490","DOIUrl":"https://doi.org/10.1097/LVT.0000000000000490","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SiLVER randomized clinical trial. 在 SiLVER 随机临床试验中验证 R3-AFP 模型对肝移植后 HCC 复发的风险预测。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-20 DOI: 10.1097/LVT.0000000000000487
Federico Piñero, Quirino Lai, Charlotte Costentin, Helena Degroote, Andreas Schnitzbauer, Edward K Geissler, Christophe Duvoux
{"title":"Validation of the R3-AFP model for risk prediction of HCC recurrence after liver transplantation in the SiLVER randomized clinical trial.","authors":"Federico Piñero, Quirino Lai, Charlotte Costentin, Helena Degroote, Andreas Schnitzbauer, Edward K Geissler, Christophe Duvoux","doi":"10.1097/LVT.0000000000000487","DOIUrl":"10.1097/LVT.0000000000000487","url":null,"abstract":"<p><p>Explant-based models for assessing HCC recurrence after liver transplantation serve as the gold standard, guiding post-liver transplantation screening and immunosuppression adjustment. Incorporating alpha-fetoprotein (AFP) levels into these models, such as the novel R3-AFP score, has notably enhanced risk stratification. However, validation of these models in high-evidence data is mandatory. Therefore, the aim of the present research was to validate the R3-AFP score in a randomized clinical trial. We analyzed the intention-to-treat population from the 2-arm SiLVER trial (NCT00355862), comparing calcineurin-based ([calcineurin inhibitors]-Group A) versus mammalian target of rapamycin inhibitors-based (sirolimus-Group B) immunosuppression for post-liver transplantation HCC recurrence. Competing risk analysis estimated sub-hazard ratios, with testing of discriminant function and calibration. Overall, 508 patients from the intention-to-treat analysis were included (Group A, n = 256; Group B, n = 252). The R3-AFP score distribution was as follows: 42.6% low-risk (n = 216), 35.7% intermediate-risk (n = 181), 19.5% high-risk (n = 99), and 2.2% very-high-risk (n = 11) groups. The R3-AFP score effectively stratified HCC recurrence risk, with increasing risk for each stratum. Calibration of the R3-AFP model significantly outperformed other explant-based models (Milan, Up-to-7, and RETREAT), whereas discrimination power (0.75 [95% CI: 0.69; 0.81]) surpassed these models, except for the RETREAT model ( p = 0.49). Subgroup analysis showed lower discrimination power in the mammalian target of rapamycin group versus the calcineurin inhibitors group ( p = 0.048). In conclusion, the R3-AFP score accurately predicted HCC recurrence using high-quality evidence-based data, exhibiting reduced performance under mammalian target of rapamycin immunosuppression. This highlights the need for further research to evaluate surveillance schedules and adjuvant regimens.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142290410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CON: Is management of ACLF better in a liver-dedicated ICU? 结论:肝脏专用重症监护室对 ACLF 的管理是否更好?
IF 4.6 2区 医学
Liver Transplantation Pub Date : 2024-09-19 DOI: 10.1097/lvt.0000000000000491
Linnea A Swanson,Elliot B Tapper,Nikhilesh R Mazumder
{"title":"CON: Is management of ACLF better in a liver-dedicated ICU?","authors":"Linnea A Swanson,Elliot B Tapper,Nikhilesh R Mazumder","doi":"10.1097/lvt.0000000000000491","DOIUrl":"https://doi.org/10.1097/lvt.0000000000000491","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival benefit of liver transplantation utilizing marginal donor organ according to ABO blood type. 根据 ABO 血型利用边缘供体器官进行肝移植的存活率。
IF 4.6 2区 医学
Liver Transplantation Pub Date : 2024-09-18 DOI: 10.1097/lvt.0000000000000460
Miho Akabane,Yuki Bekki,Yosuke Inaba,Yuki Imaoka,Carlos O Esquivel,Allison Kwong,W Ray Kim,Kazunari Sasaki
{"title":"Survival benefit of liver transplantation utilizing marginal donor organ according to ABO blood type.","authors":"Miho Akabane,Yuki Bekki,Yosuke Inaba,Yuki Imaoka,Carlos O Esquivel,Allison Kwong,W Ray Kim,Kazunari Sasaki","doi":"10.1097/lvt.0000000000000460","DOIUrl":"https://doi.org/10.1097/lvt.0000000000000460","url":null,"abstract":"BACKGROUNDThe current liver transplantation (LT) allocation policy focuses on the Model for End-Stage Liver Disease (MELD) scores, often overlooking factors like blood type and survival benefits. Understanding blood types' impact on survival benefits is crucial for optimizing the MELD 3.0 classification.METHODThis study used the United Network for Organ Sharing national registry database (2003-2020) to identify LT characteristics per ABO blood type and to determine the optimal MELD 3.0 scores for each blood type, based on survival benefits.RESULTSThe study included LT candidates aged 18 years or older listed for LT (total N=150,815; A:56,546, AB:5,841, B:18,500, O:69,928). Among these, 87,409 individuals (58.0%) underwent LT (A:32,156, AB:4,362, B:11,786, O:39,105). Higher transplantation rates were observed in AB and B groups, with lower median MELD 3.0 scores at transplantation (AB:21, B:24 vs. A/O:26, p<0.01) and shorter waiting times (AB:101 days, B:172 days vs. A:211 days, O:201 days, p<0.01). A preference for Donation after Cardiac Death (DCD) was seen in A and O recipients. Survival benefit analysis indicated that B blood type required higher MELD 3.0 scores for transplantation than A and O (Donation after Brain Death transplantation: ≥15 in B vs. ≥11 in A/O; DCD transplantation: ≥21 in B vs. ≥11 in A, ≥15 in O).CONCLUSIONThe study suggests revising the allocation policy to consider blood type for improved post-LT survival. This calls for personalized LT policies, recommending higher MELD 3.0 thresholds, particularly for individuals with type B blood.","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142269347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are there any benefits of prolonged hypothermic oxygenated perfusion? - Results from a national retrospective study. 长时间低体温氧合灌注有好处吗?- 一项全国性回顾性研究的结果。
IF 4.6 2区 医学
Liver Transplantation Pub Date : 2024-09-18 DOI: 10.1097/lvt.0000000000000476
Riccardo De Carlis,Andrea Lauterio,Andrea Schlegel,Enrico Gringeri,Damiano Patrono,Stefania Camagni,Daniele Dondossola,Daniele Pezzati,Tiziana Olivieri,Duilio Pagano,Marco Bongini,Paolo Montanelli,Matteo Ravaioli,Davide Bernasconi,Maria Grazia Valsecchi,Umberto Baccarani,Matteo Cescon,Enzo Andorno,Vincenzo Mazzaferro,Salvatore Gruttadauria,Fabrizio Di Benedetto,Davide Ghinolfi,Lucio Caccamo,Domenico Pinelli,Renato Romagnoli,Umberto Cillo,Luciano De Carlis,
{"title":"Are there any benefits of prolonged hypothermic oxygenated perfusion? - Results from a national retrospective study.","authors":"Riccardo De Carlis,Andrea Lauterio,Andrea Schlegel,Enrico Gringeri,Damiano Patrono,Stefania Camagni,Daniele Dondossola,Daniele Pezzati,Tiziana Olivieri,Duilio Pagano,Marco Bongini,Paolo Montanelli,Matteo Ravaioli,Davide Bernasconi,Maria Grazia Valsecchi,Umberto Baccarani,Matteo Cescon,Enzo Andorno,Vincenzo Mazzaferro,Salvatore Gruttadauria,Fabrizio Di Benedetto,Davide Ghinolfi,Lucio Caccamo,Domenico Pinelli,Renato Romagnoli,Umberto Cillo,Luciano De Carlis,","doi":"10.1097/lvt.0000000000000476","DOIUrl":"https://doi.org/10.1097/lvt.0000000000000476","url":null,"abstract":"BACKGROUNDDual hypothermic oxygenated perfusion (DHOPE) is increasingly being used to extend liver preservation to improve transplant logistics. However, little is known about its benefits in high-risk liver grafts. This study aimed to investigate whether prolonged DHOPE provides benefits other than improved logistics in all liver types.METHODSWe performed a national retrospective cohort study of 177 liver transplants from 12 Italian centers preserved with DHOPE for ≥4h between 2015 and 2022. A control group of 177 DHOPEs of <4h during the same period was created using 1:1 propensity score matching. The impact of risk profiles and preservation times on the outcomes was assessed using univariable and multivariable regression models.RESULTSNo significant differences in post-transplant outcomes were found between prolonged and short DHOPEs. However, the prolonged group had a significantly lower incidence of post-transplant acute kidney injury (AKI) compared to the short group (30.5% vs. 44.6%, p=0.008). Among prolonged DHOPEs, no differences in transplant outcomes were observed according to donor risk index (DRI), Eurotransplant definition for marginal grafts, and balance of risk (BAR) score. DHOPE duration was associated with a lower risk of AKI in multivariable models adjusted for DRI, Eutrotransplant marginal grafts, and BAR score. Prolonged HOPE confirmed its protective effect against AKI in a multivariable model adjusted for donor and recipient risk factors [OR: 0.412, 95%CI: 0.200-0.850, p=0.016].CONCLUSIONSProlonged DHOPE is widely used to improve transplant logistics, provides good results with high-risk grafts, and appears to be associated with a lower risk of post-transplant AKI. These results provide further insight into the important role of DHOPE in preventing post-transplant complications.","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memoriam: Ruud A.F. Krom, MD, PhD (1941-2024). 悼念Ruud A.F. Krom,医学博士(1941-2024)。
IF 4.6 2区 医学
Liver Transplantation Pub Date : 2024-09-18 DOI: 10.1097/lvt.0000000000000443
Ian P J Alwayn,Aad P van den Berg,Maureen M J Guichelaar,Bart van Hoek,Harry Janssen,Gauke Kootstra,Vincent E de Meijer,Robert J Porte,Maarten J Slooff,Russell H Wiesner
{"title":"In memoriam: Ruud A.F. Krom, MD, PhD (1941-2024).","authors":"Ian P J Alwayn,Aad P van den Berg,Maureen M J Guichelaar,Bart van Hoek,Harry Janssen,Gauke Kootstra,Vincent E de Meijer,Robert J Porte,Maarten J Slooff,Russell H Wiesner","doi":"10.1097/lvt.0000000000000443","DOIUrl":"https://doi.org/10.1097/lvt.0000000000000443","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142258294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bulevirtide improves liver function in liver transplant candidates with advanced HDV cirrhosis and severe portal hypertension. 布来韦肽可改善患有晚期 HDV 肝硬化和严重门静脉高压症的肝移植候选者的肝功能。
IF 4.6 2区 医学
Liver Transplantation Pub Date : 2024-09-13 DOI: 10.1097/lvt.0000000000000486
Alessandro Loglio,Mauro Viganò,Lucrezia Goisis,Elisa Farina,Marco E G Arosio,Paolo Marra,Claudio Farina,Stefano Fagiuoli
{"title":"Bulevirtide improves liver function in liver transplant candidates with advanced HDV cirrhosis and severe portal hypertension.","authors":"Alessandro Loglio,Mauro Viganò,Lucrezia Goisis,Elisa Farina,Marco E G Arosio,Paolo Marra,Claudio Farina,Stefano Fagiuoli","doi":"10.1097/lvt.0000000000000486","DOIUrl":"https://doi.org/10.1097/lvt.0000000000000486","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142202704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Time for validating GEMA-Na in the United States for liver transplant waiting list prioritization. 致编辑:在美国验证 GEMA-Na 用于肝移植候选名单优先排序的时机已到。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-10 DOI: 10.1097/LVT.0000000000000483
Manuel L Rodríguez-Perálvarez, Avik Majumdar, Emmanuel Tsochatzis
{"title":"Letter to the Editor: Time for validating GEMA-Na in the United States for liver transplant waiting list prioritization.","authors":"Manuel L Rodríguez-Perálvarez, Avik Majumdar, Emmanuel Tsochatzis","doi":"10.1097/LVT.0000000000000483","DOIUrl":"10.1097/LVT.0000000000000483","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信